Publicação científica trimestral do CREMERJ - número 4 - 2022

29 Med. Ciên. e Arte , Rio de Janeiro, v.1, n.4, p.13-30, out-dez 2022 Lúpus Eritematoso Sistêmico: o que o clínico precisa saber Mirhelen Mendes de Abreu T ou sua interação, células dendríticas, IFN e outras citocinas e, finalmente, baixa dose de IL-2 para impulsionar a regulação da função de célula T. Tratamento global da doença e do paciente ainda é limitado. Indicadores que incluam a perspectiva do paciente quanto ao progresso do cuidado da sua doença também podem favorecer o desenvolvimento de medicamentos para diferentes subtipos da doença. (18,23) REFERÊNCIAS 1. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 2010; 69:1603-11. 2. Smith CD, Cyr M. The history of lupus erythematosus from Hippocrates to Osler. Rheum Dis Clin North Am 1988; 14:1-14. 3. Mallavarapu RK, Grimsley EW. The history of lupus erythematosus. South Med J 2007; 100:896-8. 4. Gergianaki I, Fanouriakis A, Repa A, et al. Epidemiology and burden of systemic lupus erythematosus in a southern European population: data from the community-based lupus Registry of Crete, Greece. Ann Rheum Dis 2017; 76:1992-2000. 5. Nikolopoulos DS, Kostopoulou M, Pieta A, et al. Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. Lupus Sci Med 2020; 7. 6. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016; 12:605-20. 7. Kuo C-F, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med 2015; 175:1518. 8. Bertsias GK, Pamfil C, Fanouriakis A, et al. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol 2013; 9:687-94. 9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725. 10. Petri M, Orbai A-M, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677-86. 11. Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015; 74:2117-22. 12. Tselios K, Gladman DD, Touma Z, et al. Disease course patterns in systemic lupus erythematosus. Lupus 2019; 28:114-22. 13. Adamichou C, Nikolopoulos D, Genitsaridi I, et al. In an early SLE cohort the ACR1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis 2020; 79:232-41. 14. Zen M, Iaccarino L, Gatto M, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 2018; 77:104-10. 15. Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther 2015; 17:183.